Sponsors (3)
The bill increases public safety by bringing tianeptine and its analogues under explicit federal control and enforcement, but that greater regulation may restrict access and raise costs for legitimate users while imposing compliance burdens and criminalization risks.
Patients and other consumers: fewer unregulated or adulterated tianeptine products will be available as the bill creates controls that reduce illegal sales, improving consumer safety.
Law enforcement, prosecutors, and federal agencies: DEA/DOJ gain an explicit legal and regulatory basis to schedule, seize, and prosecute illegal tianeptine distribution and possession, clarifying enforcement authority.
Regulated entities: manufacturers and distributors that must comply with the Controlled Substances Act will have clearer regulatory rules covering tianeptine and its analogues.
People legally using or obtaining tianeptine: may face reduced access or higher costs if the drug becomes scheduled or more tightly controlled.
Individuals who obtained tianeptine in unregulated markets: could face increased arrests, prosecutions, or criminal penalties as possession and distribution become more clearly actionable.
Small retailers and manufacturers: will incur additional compliance costs to meet CSA requirements for a newly scheduled substance.
Based on analysis of 2 sections of legislative text.
Adds tianeptine and its analogues (and salts/isomers) to Schedule III of the Controlled Substances Act, effective in 90 days.
Official title: To amend the Controlled Substances Act to provide for the scheduling of tianeptine as a schedule III substance, and for other purposes.
Introduced May 20, 2025 by James Varni Panetta · Last progress May 20, 2025
Adds tianeptine and its analogues, salts, isomers, and salts of isomers to Schedule III of the Controlled Substances Act, making possession, distribution, and manufacture subject to federal controls and penalties under that schedule. The change takes effect 90 days after the law is enacted.